GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Cyclically Adjusted Revenue per Share

Endologix (Endologix) Cyclically Adjusted Revenue per Share : $0.00 (As of Jun. 2020)


View and export this data going back to 1996. Start your Free Trial

What is Endologix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Endologix's adjusted revenue per share for the three months ended in Jun. 2020 was $1.199. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-05), Endologix's current stock price is $0.0199. Endologix's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2020 was $0.00. Endologix's Cyclically Adjusted PS Ratio of today is .


Endologix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Endologix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Cyclically Adjusted Revenue per Share Chart

Endologix Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Endologix Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Endologix's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Endologix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endologix's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Endologix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Endologix's Cyclically Adjusted PS Ratio falls into.



Endologix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Endologix's adjusted Revenue per Share data for the three months ended in Jun. 2020 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=1.199/108.7673*108.7673
=1.199

Current CPI (Jun. 2020) = 108.7673.

Endologix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201009 3.660 92.162 4.319
201012 3.375 92.474 3.970
201103 3.317 94.283 3.827
201106 3.411 95.235 3.896
201109 3.915 95.727 4.448
201112 4.085 95.213 4.667
201203 4.255 96.783 4.782
201206 4.346 96.819 4.882
201209 4.353 97.633 4.849
201212 4.746 96.871 5.329
201303 4.789 98.209 5.304
201306 5.185 98.518 5.724
201309 5.302 98.790 5.837
201312 5.576 98.326 6.168
201403 5.038 99.695 5.496
201406 6.113 100.560 6.612
201409 5.673 100.428 6.144
201412 5.505 99.070 6.044
201503 5.452 99.621 5.953
201506 5.838 100.684 6.307
201509 5.638 100.392 6.108
201512 5.771 99.792 6.290
201603 5.526 100.470 5.982
201606 6.211 101.688 6.643
201609 6.322 101.861 6.751
201612 5.738 101.863 6.127
201703 5.138 102.862 5.433
201706 5.833 103.349 6.139
201709 5.507 104.136 5.752
201712 5.260 104.011 5.501
201803 5.051 105.290 5.218
201806 5.297 106.317 5.419
201809 4.078 106.507 4.165
201812 3.531 105.998 3.623
201903 3.432 107.251 3.481
201906 1.997 108.070 2.010
201909 1.859 108.329 1.867
201912 1.830 108.420 1.836
202003 1.421 108.902 1.419
202006 1.199 108.767 1.199

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Endologix  (OTCPK:ELGXQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Endologix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Endologix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Endologix (Endologix) Business Description

Traded in Other Exchanges
N/A
Address
2 Musick, Irvine, CA, USA, 92618
Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.
Executives
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko director, officer: CEO and Director C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Matthew Thompson officer: Chief Medical Officer 2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady officer: Controller and Corp Secretary 2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto officer: Interim CFO 2 MUSICK IRVINE CA 92618
Jeff Fecho officer: Chief Quality Officer ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob officer: Chief Financial Officer 2 MUSICK IRVINE CA 92618
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John Zehren officer: Chief Commercial Officer 2 MUSICK IRVINE CA 92618
Jeremy B. Hayden officer: General Counsel 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F director 2 MUSICK IRVINE CA 92618